Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. - Wikidata - awgldk - TriplyDB

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

http://www.wikidata.org/entity/Q33869732

about

Is GLP-1 a hormone: Whether and When?Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress.Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans L-glutamine and whole protein restore first-phase insulin response and increase glucagon-like peptide-1 in type 2 diabetes patients.β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity.Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes.Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test.Removal of duodenum elicits GLP-1 secretion.The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways.Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study.Contributions of fat and protein to the incretin effect of a mixed meal.Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe.Changes in post-prandial glucose and pancreatic hormones, and steady-state insulin and free fatty acids after gastric bypass surgery.Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass.Endogenously released GLP-1 is not sufficient to alter postprandial glucose regulation in the dog The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.Diabetes remission following metabolic surgery: is GLP-1 the culprit?Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.Pharmacokinetic/pharmacodynamic modeling of GLP-1 in healthy rats.The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs.GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.The Dietary Furocoumarin Imperatorin Increases Plasma GLP-1 Levels in Type 1-Like Diabetic Rats.Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion.Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.Correlation of the incretin effect with first- and second-phase insulin secretions in Koreans with various glucose tolerance statuses.The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice.Dysregulated bile acid synthesis and dysbiosis are implicated in Western diet-induced systemic inflammation, microglial activation, and reduced neuroplasticity Glutamine Reduces Postprandial Glycemia and Augments the Glucagon-Like Peptide-1 Response in Type 2 Diabetes Patients

P2860

Q26749196-516AF861-009C-48D6-BAA7-3EBFBE8028A9 Q26995145-A21404FA-D750-448E-8BF6-B9BF0513EF94 Q27027920-45016256-DBC8-4BFC-B22F-B1AA313651DC Q33682506-57027960-0C38-4127-9B4E-6D2F65BF3DBB Q33812543-999F9D57-A282-4358-AE7D-752F9819BB83 Q35179981-FEC51539-AE87-4A7C-9D54-48D1EB79EDF2 Q35585816-F8443EB6-4644-4836-92BE-6D08359D0BAD Q35680897-8A7D8A29-5FAE-441F-866D-6F3C2218CA2C Q35744498-460F09CA-D32C-4B8A-B5D6-9A7421B9B1DB Q35797043-75B5C323-9A94-4F57-AE28-0D572FD71523 Q36182510-DF574C8A-C25C-4554-810C-A2E3077B3B2A Q36182540-0895E95B-3F29-49E3-BD23-8A6899BE3163 Q36339659-5381148A-64D8-41CF-A80E-1F150684F78E Q36868293-3204EF22-F353-4C5B-8982-0161219747F9 Q36902183-C4B32E47-1F32-4432-A80B-F6A0780BB7CF Q36950218-BDE18DB8-C907-4208-94F2-3FE5AFE307D5 Q36994382-1F0548A4-09B2-4292-90CB-FA24740D2234 Q37092070-F4687024-890D-4E8F-BE0A-A3E7DCD24FE9 Q37110621-46362AD1-BE6A-4E57-84F9-6B13ADF7D791 Q37212797-43050AC8-0513-47C7-B9FF-34B16CD89BAE Q37496296-9A61871C-1FDF-47F1-9DB0-1A6124EC34C8 Q37575821-2AA3EE55-528B-4D38-889E-0D42D6F4165B Q37620091-62AB5D09-C2A1-4545-81E0-6B8984D25FBF Q37670181-E12E3C1A-D3A5-4331-B284-A9E10AF585B9 Q37726837-562D4486-EB85-4B38-B331-E7935E55EDD7 Q38088195-3B6DF1A0-DD65-4CD6-A827-DC6A82984A83 Q38129779-5718C274-BD92-4A92-BD9F-4B86F5ECAC63 Q38616170-434ABA01-63A3-4B1C-9FE3-DF47041E59E3 Q41845173-A6900FA6-693F-4D9C-9297-594F4353BF7C Q41849970-F13AC989-E7B6-4C15-83A5-2DB770D36E55 Q41962105-6E87593E-0E81-4811-AE6F-A3CBA643C74F Q45985301-852711C0-7A6D-4536-AC64-CAC946178A3D Q47113797-D13AE23C-0E2E-4A13-95AF-3AEC4C0AF36F Q48015498-4FC8DF41-10C0-4842-BF8A-F7E4FA0FBA04 Q48169180-49925DAD-F17E-4433-9667-BBC3AD72793D Q51010554-52655EA3-0168-4F62-8A8D-9299A1F43ADC Q51031191-4B4DCBDC-4859-4005-813A-50BA75658728 Q51091690-1BCC2D11-F22B-42D9-B5C9-9BB07949BDC2 Q57101020-52294EEB-4BA9-4207-A251-024B81F517F5 Q58448029-1846E50C-5317-467A-AF6D-FBC74AF73971

P2860

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

http://www.wikidata.org/entity/Q33869732

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

@ast

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

@en

type

label

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

@ast

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

@en

prefLabel

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

@ast

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

@en

P1433

Q33869732-44117814-9420-48CB-987C-9191846EAF1A

P1476

Q33869732-8CD11944-683D-4FE2-BC9A-545AD2CF9720

P2093

Q33869732-0759D782-FC89-493A-8F72-8BEF24837EFD

Q33869732-80516A2A-49EB-46CA-AEFA-FF234D699D4E

Q33869732-91F27605-18C6-4E3C-996D-79FD43C60BFE

Q33869732-FE38ABEE-62EE-4E7E-8BD9-1661745C57E3

P2860

Q33869732-03468D55-4913-4D16-8335-3ABAD70DA0A0

Q33869732-0671BF49-D03E-4BDC-9116-ED895AA9002C

Q33869732-0E741C3C-EE36-4E1B-AD5F-C03780CAB61D

Q33869732-0FAFBE97-5096-4755-A507-0BE8709D7C6D

Q33869732-10D4451E-EF7F-4F97-A10C-2A0ECEB30C34

Q33869732-16296E07-4CB0-4A4E-B4E9-EF9A26B3D386

Q33869732-1AAD6B9A-010B-4CAD-9FC9-B4E37390B001

Q33869732-20944272-3D08-40B2-ACB8-7A9A5CCEDA86

Q33869732-2F1DC0A1-0664-4F21-947A-CF255037890B

Q33869732-30488988-9D97-4306-926D-DE7FEDCDAD26

P304

Q33869732-8A243451-75D3-4049-B492-D0723E5C2221

P31

Q33869732-44014097-FAD7-443F-9B68-EAC99B91B022

P356

Q33869732-2B1EF8E9-151C-4560-9E46-62A2939EB652

P407

Q33869732-2FDC64E6-DF01-4B06-A876-D82BA1B3E043

P433

Q33869732-8FCCA219-5A5C-411D-907C-DD011E12DDFC

P478

Q33869732-B3B63716-BBF7-4243-AD83-D2CE1B9DA1E1

P577

Q33869732-76C5464C-B43D-4DBF-AAC8-D18C326FB5BD

P5875

Q33869732-5DD5A783-E559-4B0B-84F1-0F7CDC6858D5

P698

Q33869732-B6EAD148-817D-4763-820E-1C57C1ECB00E

P921

Q33869732-AD93954E-CB5C-4763-B5A6-499D79441408

Q33869732-EE0958A1-3395-413B-A864-1FF253B35D78

P932

Q33869732-2AE45D83-D958-4A18-A3F0-450187906AFF

P356

P1433

P1476

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

@en

P2093

Benedict Aulinger

http://www.w3.org/2001/XMLSchema#string

David A D'Alessio

http://www.w3.org/2001/XMLSchema#string

Marzieh Salehi

http://www.w3.org/2001/XMLSchema#string

Ronald L Prigeon

http://www.w3.org/2001/XMLSchema#string

P2860

Is glucagon-like peptide 1 an incretin hormone?

The biology of incretin hormones.

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.

Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake

Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels.

Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.

P304

1330-1337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB09-1253

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41848476

http://www.w3.org/2001/XMLSchema#string

P698

20215429

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2874693

http://www.w3.org/2001/XMLSchema#string